May 2, 2025 Release Highlights Copied

05/02/20252025 VBCRelease note

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard will be updated to reflect the below refinement(s):

Measure	Description	Practice Impact
PIMSH 1: Advance Care Planning in Metastatic Disease	Denominator look back period changed from 2 years prior to and 6 months after the measurement period to include all patients with stage 4 cancer diagnosed between July 1 of the previous performance period through June 30 of the current performance period Removed E/M code G0439 from the denominator Changed denominator criteria to include only patients with solid tumors	Decrease in overall numerator and/or denominator counts
PIMSH 13: Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy	Denominator : Modified assessment period for stage IV nsNSCLC diagnosis to include patients diagnosed between July 1 of the previous performance period through June 30 of the current performance period Denominator Exclusion: Removed denominator exclusion for insufficient tissue; added denominator exclusion for patients on clinical trial Numerator: If positive biomarker results are received for the values listed AND the correct drug is given = Numerator Met If positive biomarker results are received and the correct drug IS NOT given, THEN Numerator Not Met Grace period of 6 weeks post receipt of biomarker results to switch to correct therapy Added KRAS, ERBB2 mutation testing for all actionable biomarkers at Stage 4 diagnosis of NSCLC	Increase in overall numerator and/or denominator counts
MIPS 130: Current Medications Documentation	Removed age restriction. Patient no longer has to be 18 or older is apart of the denominator criteria.	Very minimal impact overall performance rate

Measure

Description

Practice Impact

PIMSH 1: Advance Care Planning in Metastatic Disease

Denominator look back period changed from 2 years prior to and 6 months after the measurement period to include all patients with stage 4 cancer diagnosed between July 1 of the previous performance period through June 30 of the current performance period
Removed E/M code G0439 from the denominator
Changed denominator criteria to include only patients with solid tumors

Decrease in overall numerator and/or denominator counts

PIMSH 13: Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy

Denominator :

Modified assessment period for stage IV nsNSCLC diagnosis to include patients diagnosed between July 1 of the previous performance period through June 30 of the current performance period

Denominator Exclusion:

Removed denominator exclusion for insufficient tissue; added denominator exclusion for patients on clinical trial

Numerator:

If positive biomarker results are received for the values listed AND the correct drug is given = Numerator Met
If positive biomarker results are received and the correct drug IS NOT given, THEN Numerator Not Met
Grace period of 6 weeks post receipt of biomarker results to switch to correct therapy
Added KRAS, ERBB2 mutation testing for all actionable biomarkers at Stage 4 diagnosis of NSCLC

Increase in overall numerator and/or denominator counts

MIPS 130: Current Medications Documentation

Removed age restriction. Patient no longer has to be 18 or older is apart of the denominator criteria.

Very minimal impact overall performance rate

Status of Dashboard Updates for 2025

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.

Measure	Description
MIPS Quality Measures Dashboard
MIPS #130	Current Medications Documentation
PIMSH #1	Advance Care Planning in Metastatic Disease
PIMSH #13	Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy